Hot Biotech Upgrades: Zenas BioPharma and BioAge Labs Shine Bright
Wall Street analysts are bullish on Zenas BioPharma and BioAge Labs with strong upgrades, highlighting near-term FDA potential and promising drug data for big growth in 2026.
/ 4 items
#ZBIO↓
Zenas BioPharma Crashes 53% Despite Meeting Trial Goals—Why Investors Aren't Buying It
Zenas BioPharma stock plunges over 50% after Phase 3 obexelimab trial results disappoint Wall Street, despite meeting all endpoints in rare autoimmune disease study.
Biotech Stocks Update: ZBIO, SPRB, CNTX, OVID Ratings
Citi, H.C. Wainwright, JonesResearch, and LifeSci Capital share new ratings and price targets on Zenas BioPharma, Spruce Biosciences, Context Therapeutics, and Ovid Therapeutics.
Zenas BioPharma Secures $2B+ Deal for MS Drug from InnoCare
Zenas BioPharma acquires global rights to orelabrutinib, an experimental multiple sclerosis drug from InnoCare Pharma, in a licensing deal worth over $2 billion with $120M funding secured.